Arcturus prioritization of mRNA therapeutics pipeline extends cash runway into 2028

 ARCT-032 (CF) Phase 2 interim data from first two cohorts expected in mid-2025

ARCT-032 (CF) Phase 2 expected to complete enrollment by year end

ARCT-810 (OTC) Phase 2 interim data expected Q2 2025

Investor conference call at 4:30 p.m. ET today

Earnings Call: Monday, May 12, 2025 @ 4:30 PM ET

• Domestic: 1-800-267-6316
• International: 1-203-518-9783
• Conference ID: ARCTURUS
• Webcast: Link

https://www.businesswire.com/news/home/20250512026043/en/Arcturus-Therapeutics-Announces-First-Quarter-2025-Financial-Update-and-Pipeline-Progress